We expect RubrYc’s artificial intelligence (AI)-Driven Drug Discovery Engine to significantly strengthen our drug discovery capabilities as an integral part of our early stage drug discovery center in San Diego, California.
So, what’s so novel about another “AI” Platform?
In short, the AI Drug Discovery Engine is designed to find antibodies against the most challenging targets – with the greatest potential success rates – where others have struggled or failed.
It does this by identifying, engineering, and optimizing artificial proteins that mimic the exact shape of complex epitopes, including subdominant epitopes, to discover highly promising therapeutic antibodies. An epitope is the specific section of a target protein to which antibodies bind. The range of potential epitopes or binding sites on a target is enormous. But not all epitopes are created equally.
Traditional drug discovery has allowed the immune system to do the picking of epitopes and thus biasing antibody selection towards the ones most commonly recognized by the immune system. Often, the best epitope for developing a new drug is harder to find or is overshadowed by other more immunodominant epitopes.